Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Minyong | - |
dc.contributor.author | Park, Jae Young | - |
dc.contributor.author | Jeong, Chang Wook | - |
dc.contributor.author | Hwang, Eu Chang | - |
dc.contributor.author | Song, Cheryn | - |
dc.contributor.author | Hong, Sung-Hoo | - |
dc.contributor.author | Kwak, Cheol | - |
dc.contributor.author | Chung, Jinsoo | - |
dc.contributor.author | Sung, Hyun Hwan | - |
dc.contributor.author | Jeon, Hwang Gyun | - |
dc.contributor.author | Jeong, Byong Chang | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Jeon, Seong Soo | - |
dc.contributor.author | Lee, Hyun Moo | - |
dc.contributor.author | Choi, Han Yong | - |
dc.contributor.author | Seo, Seong Il | - |
dc.date.accessioned | 2021-09-02T04:09:40Z | - |
dc.date.available | 2021-09-02T04:09:40Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2018-11 | - |
dc.identifier.issn | 0022-5347 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/71937 | - |
dc.description.abstract | Purpose: In this study we evaluated conditional survival probabilities in patients with metastatic renal cell carcinoma who underwent first line tyrosine kinase inhibitor therapy. We also identified predictors of conditional survival with time. Materials and Methods: We retrospectively reviewed clinical data on 1,659 individuals with metastatic renal cell carcinoma in the Korean Renal Cancer Study Group database, of whom the records of 1,131 were finally analyzed. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities using the formula, conditional survival (alpha vertical bar beta = S(alpha+ beta)/S(beta), indicating the likelihood of additional alpha years survivorship in person who has already survived for beta years after initial therapy. S(chi) represents the actual survival rate. Multivariate Cox regression model was used to identify predictors of conditional survival with time. Results: Six, 12, 18, 24 and 36-month conditional overall survival gradually increased in patients at all additional survival times after initial treatment compared to patient baseline survival estimations. While the actual overall survival rate decreased with time, the 36-month conditional overall survival rate was calculated as 7.3% higher in patients who had already survived 36 months compared to baseline estimations at the time of initial tyrosine kinase inhibitor treatment. Furthermore, predictors of conditional overall survival changed with time. Only previous metastasectomy remained a key prognosticator of conditional overall survival until 36 months of survival following initial tyrosine kinase inhibitor treatment. Conclusions: Conditional survival improved with time after initial tyrosine kinase inhibitor treatment in patients with metastatic renal cell carcinoma. Our study offers valuable information for practical survival estimations and relevant prognosticators in patients with metastatic renal cell carcinoma who receive first line tyrosine kinase inhibitor. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.subject | NEPHRECTOMY | - |
dc.subject | MANAGEMENT | - |
dc.subject | FUTURE | - |
dc.subject | CANCER | - |
dc.title | Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Jae Young | - |
dc.identifier.doi | 10.1016/j.juro.2018.06.030 | - |
dc.identifier.scopusid | 2-s2.0-85053637988 | - |
dc.identifier.wosid | 000446884900070 | - |
dc.identifier.bibliographicCitation | JOURNAL OF UROLOGY, v.200, no.5, pp.989 - 994 | - |
dc.relation.isPartOf | JOURNAL OF UROLOGY | - |
dc.citation.title | JOURNAL OF UROLOGY | - |
dc.citation.volume | 200 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 989 | - |
dc.citation.endPage | 994 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.subject.keywordPlus | NEPHRECTOMY | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | FUTURE | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordAuthor | kidney | - |
dc.subject.keywordAuthor | carcinoma | - |
dc.subject.keywordAuthor | renal cell | - |
dc.subject.keywordAuthor | neoplasm metastasis | - |
dc.subject.keywordAuthor | mortality | - |
dc.subject.keywordAuthor | protein-tyrosine kinases | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.